Alternative analytical techniques, such as immunohistochemistry (IHC), fluorescence in situ hybridization (FISH) and RT-qPCR have reduced TAT and are therefore commonly integrated in customized fast track panels to screen for certain biomarkers in NSCLC (e.g., IHC as a surrogate marker for anaplastic lymphoma kinase [ALK] fusions, FISH for ALK and ROS proto-oncogene 1 [ROS1] fusions, RT-qPCR for EGFR variants) [12]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.